Ascendis Pharma (ASND) Q3 2024 earnings summary

Executive summary

• Three rare endocrinology programs delivered pivotal data, with SkyTrofa and YorviPath approved and commercialized in the U.S. and Europe, and TransCon CNP preparing for regulatory submission in 2025.

• SkyTrofa achieved a leading position in the U.S. pediatric growth hormone market, with significant year-over-year demand growth and broader market access.

• YorviPath is set for a major U.S. launch in January 2025, targeting a large, underserved adult hypoparathyroidism population, with Q3 ex-U.S. revenue of €8.5 million and over 600 patients on treatment.

• Novo Nordisk collaboration expands the TransCon platform into obesity and diabetes, with a $100 million upfront payment, up to $285 million in milestones, and future royalties.

Financial highlights

• Q3 2024 total revenue was €57.8 million, up from €48.0 million in Q3 2023, driven by SkyTrofa and YorviPath.

• SkyTrofa Q3 2024 revenue was €47.2 million, flat year-over-year due to higher sales deductions despite >60% volume growth; nine-month revenue rose 21% to €138.5 million.

• YorviPath ex-U.S. Q3 revenue grew over 60% to €8.5 million.

• R&D expenses declined 34% year-over-year to €73.5 million; SG&A rose to €69.8 million due to commercial expansion.

• Net loss for Q3 2024 was €99.2 million (€1.72 per share), improved from €162.2 million (€2.88 per share) in Q3 2023.

• Cash and equivalents at quarter-end were €625.5 million, not including the pending Novo Nordisk payment.

Outlook and guidance

• Full-year 2024 SkyTrofa revenue (excluding prior period deductions) is expected at €200–220 million.

• Total 2024 operating expenses (SG&A and R&D) are projected at approximately €600 million, including YorviPath U.S. launch costs.

• Cash flow break-even remains a goal by end of 2025.

• TransCon CNP NDA submission for achondroplasia planned for Q1 2025; MAA submission in Q3 2025.

• Topline results from Phase 2 New InsiGHTS Trial in Turner syndrome expected Q4 2024; COACH trial data expected Q2 2025.